Please note that the ANZCTR website will be unavailable from 9am until 9.30am (AEST) on Monday 22nd July for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00520533




Registration number
NCT00520533
Ethics application status
Date submitted
22/08/2007
Date registered
24/08/2007
Date last updated
28/02/2013

Titles & IDs
Public title
Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Scientific title
A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Secondary ID [1] 0 0
LUD2007-004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Renal Cell Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Chimeric monoclonal antibody cG250
Treatment: Drugs - Sunitinib malate

Experimental: On Study - Treatment (cycle 1):
cG250 10mg/m² IV weekly x5 doses (1st & 5th doses trace-labelled with ¹²4I)
Sunitinib 50 mg/day orally x 4 weeks commencing day 8
Followed by two week break
Treatment (cycle 2 - investigator discretion):
cG250 10mg/m² IV weekly x4 doses
Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)
Followed by two week break


Other interventions: Chimeric monoclonal antibody cG250
First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (¹²4I-cG250)
Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No ¹²4I-cG250 will be used in the 2nd cycle.
Up to 2 cycles available.

Treatment: Drugs: Sunitinib malate
First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.
Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.
Up to 2 cycles available on-study.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and Tolerability of cG250 and sunitinib in patients with advanced RCC: Adverse events of cG250 administered concurrently with sunitinib
Timepoint [1] 0 0
7 -13 weeks
Secondary outcome [1] 0 0
Tumour response assessed according to standard clinical criteria (RECIST)
Timepoint [1] 0 0
7 - 13 weeks
Secondary outcome [2] 0 0
Presence of radioactivity in tumour and whole body, assessed by ¹²4I-cG250 PET imaging, serum levels of monoclonal antibody cG250 pharmacokinetics (¹²4I activity and ELISA)
Timepoint [2] 0 0
7 weeks
Secondary outcome [3] 0 0
Serum HACA assayed by ELISA
Timepoint [3] 0 0
7 - 13 weeks
Secondary outcome [4] 0 0
Tumour glycolytic metabolism and tumour blood flow assessment by serial [18]F-FDG and [15]O-H2O PET scans
Timepoint [4] 0 0
7 weeks

Eligibility
Key inclusion criteria
- Metastatic or unresectable Renal Cell Cancer (with clear cell component).

- Measurable disease by RECIST on CT with at least one measurable lesion 2 cm or greater
in diameter, which is deemed to be assessable by PET imaging.

- At least 4 weeks after chemotherapy, radiotherapy or immunotherapy (6 weeks for
nitrosourea drugs).

- Expected survival at least 3 months.

- Karnofsky performance status (KPS) of 70% or greater.

- Age 18 years or older.

- Vital laboratory parameters within normal, or protocol specified ranges.

- Left ventricular ejection fraction greater than 55% on GCBP scan.

- Systolic blood pressure =150mmHg and diastolic blood pressure =90mmHg

- Able to give written informed consent.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior exposure to cG250 monoclonal antibody (exception: no circulating human
anti-chimeric antibody to cG250).

- Prior treatment with VEGF-targeting agents (e.g. bevacizumab) or multi-kinase
inhibitors (e.g. sorafenib) not including sunitinib. (Patients currently receiving
sunitinib may be eligible if tolerating a stable dose of sunitinib on a four week on /
two week off regimen, with toxicity due to sunitinib = CTCAE grade 2; and for whom the
investigator deems it clinically reasonable to withhold sunitinib for at least four
weeks prior to commencement of study treatment.)

- Active central nervous system (CNS) metastases (exception: CNS metastases adequately
treated (surgery or radiotherapy) with no progression for at least three months).

- Known HIV positivity.

- Clinically significant heart disease.

- History of hypertension requiring hospitalisation.

- Other serious illnesses, eg, serious infections requiring antibiotics, bleeding
disorders.

- Major surgery or radiation therapy within 4 weeks prior to, or planned within 6 weeks
of starting the study treatment. (Prior palliative radiotherapy to metastatic
lesion(s) permitted, provided at least one measurable lesion was not irradiated or has
progressed following radiotherapy)

- Severe haemorrhage within 4 weeks prior to starting the study treatment.

- Any of the following within the 12 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident or transient
ischemic attack, or pulmonary embolism.

- Pre-existing thyroid abnormality with unstable thyroid function despite medication.

- Ongoing moderate to severe cardiac dysrhythmias, any severity of atrial fibrillation,
or prolongation of the QTc interval to greater than 450 msec for males or 470 msec for
females.

- Participation in a clinical trial involving another investigational agent within 4
weeks.

- Pregnancy or breastfeeding.

- Women of childbearing potential not using a medically acceptable means of
contraception.

- Psychiatric or addictive disorders that may compromise the ability to give informed
consent.

- Not available for follow-up assessment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Austin Health (Ludwig Institute Oncology Unit) - Heidelberg (Melbourne)
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg (Melbourne)

Funding & Sponsors
Primary sponsor type
Other
Name
Ludwig Institute for Cancer Research
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Pfizer
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Wilex
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This clinical trial explores the safety, efficacy, and effects on functional imaging of the
combination of cG250 monoclonal antibody administered intravenously weekly in combination
with daily oral sunitinib, in patients with advanced renal cell carcinoma.
Trial website
https://clinicaltrials.gov/show/NCT00520533
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
A/Prof Ian D Davis, FRACP, FAChPM, MBBS, PhD
Address 0 0
Ludwig Institute for Cancer Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00520533